- Conditions
- Hemophilia B
- Interventions
- FLT180a
- Biological
- Lead sponsor
- University College, London
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2593–2616
of 10,850
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
- Interventions
- clofarabine, cyclophosphamide
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 2 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pompe Disease
- Interventions
- Rituximab, Miglustat
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Leigh Syndrome
- Interventions
- EPI-743
- Drug
- Lead sponsor
- PTC Therapeutics
- Industry
- Eligibility
- 1 Year to 18 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2023
- U.S. locations
- 4
- States / cities
- Stanford University, California • Akron, Ohio • Houston, Texas + 1 more
- Conditions
- Sickle Cell Disease
- Interventions
- Blood draw, Nasopharyngeal wash
- Other
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Encephalopathy, Developmental Delay and Behavioral Changes, Cord Tumor Compression or Instability, Cord Tethering or Malformation
- Interventions
- Intermittent Propofol Sedation, Continuous Propofol Sedation
- Procedure
- Lead sponsor
- Corewell Health West
- Other
- Eligibility
- 1 Month to 18 Years
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Hypertension
- Interventions
- 6R-BH4 (sapropterin dihydrochloride)
- Drug
- Lead sponsor
- BioMarin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 24
- States / cities
- Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 21 more
- Conditions
- Gout
- Interventions
- Denosumab
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 30 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cystic Fibrosis
- Interventions
- Tobramycin for Inhalation
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 6 Months to 5 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 9
- States / cities
- Palo Alto, California • Denver, Colorado • Baltimore, Maryland + 6 more
- Conditions
- Long QT Syndrome
- Interventions
- LQT-1213, Placebo
- Drug · Other
- Lead sponsor
- Thryv Therapeutics
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Healthy
- Interventions
- Whole grain oats and barley
- Other
- Lead sponsor
- Tufts University
- Other
- Eligibility
- 40 Years to 70 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Genetic Disease, Genetic Syndrome
- Interventions
- Genetic Enrollees
- Genetic
- Lead sponsor
- Nicklaus Children's Hospital f/k/a Miami Children's Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2070
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Vascular Ehlers-Danlos Syndrome
- Interventions
- Enzastaurin, Placebo
- Drug
- Lead sponsor
- Aytu BioPharma, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Englewood, Colorado
- Conditions
- Gout, Hyperuricemia
- Interventions
- [14C] LC350189
- Drug
- Lead sponsor
- LG Chem
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Atopic Dermatitis
- Interventions
- PF-04965842 200 mg, PF-04965842 100 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 9
- States / cities
- Encinitas, California • Los Angeles, California • Largo, Florida + 5 more
- Conditions
- Hypoparathyroidism, DiGeorge Syndrome
- Interventions
- PTH 1-34
- Drug
- Lead sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
- NIH
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Arthralgia, Bunion, Hallux Valgus, Pain
- Interventions
- Tapentadol (CG5503), oxycodone, placebo
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 901 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 7
- States / cities
- Glendale, California • Pasadena, Maryland • Austin, Texas + 4 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- VECTTOR
- Device
- Lead sponsor
- Alan Neuromedical Technologies, LLC
- Industry
- Eligibility
- 8 Years to 20 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Tourette Syndrome
- Interventions
- Modified Atkins diet
- Dietary Supplement
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Citrate Transporter Deficiency, Epilepsy, Rare Diseases, Movement Disorders, Genetic Disorder, SLC13A5 Deficiency, EIEE25, Kohlschutter-Tonz Syndrome (non-ROGDI), 17p13.1 Deletions Confined to SLC13A5 Gene, Citrate Transporter Disorder
- Interventions
- Not listed
- Lead sponsor
- TESS Research Foundation
- Other
- Eligibility
- Not listed
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Telangiectasia, Hereditary Hemorrhagic, Epistaxis
- Interventions
- Sterile saline, Bevacizumab, Estriol, Tranexamic Acid
- Drug
- Lead sponsor
- James Gossage
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 3 more
- Conditions
- Von Hippel-Lindau Syndrome
- Interventions
- Ranibizumab
- Drug
- Lead sponsor
- National Eye Institute (NEI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Congenital Bleeding Disorder, Haemophilia A
- Interventions
- turoctocog alfa pegol
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 0 Years to 11 Years · Male only
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 24
- States / cities
- Phoenix, Arizona • Long Beach, California • Orange, California + 20 more
- Conditions
- Cardiomyopathy, Dilated
- Interventions
- Not listed
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • St Louis, Missouri • New York, New York + 4 more